Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kedia GT et al. - The results have provide additional evidence that the function of prostatic smooth muscle is under the control of peptidergic and cyclic nucleotide (cyclic guanosine monophosphate, cyclic adenosine monophosphate)-mediated pathways. This might give a rationale for the use of drugs interacting with cyclic guanosine monophosphate or cyclic adenosine monophosphate signaling, such as PDE inhibitors or nitric oxide donors, in the pharmacotherapy of the benign prostatic syndrome.

Today in Clinical Pharmacology...keeping you current

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research, 11/20/09

Extended-Release Doxazosin for Treatment of Renal Transplant Recipients With Benign Prostatic Hyperplasia
Transplantation Proceedings, 11/20/09

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
European Journal of Endocrinology, 11/19/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address